To the Editor:We conducted a randomised, double-blind, placebocontrolled trial of an oral faecal microbiota transplantation (FMT) intervention in children with autism spectrum disorder (ASD), and observed that there were differences in pre-and post-FMT intervention changes in the social domain scores of the Vineland Adaptive Behaviour Scale, third version (Vineland-3), with no severe adverse events (AEs) related to FMT occurring.Multiple studies have documented variations in the gut microbiota (GM) between children with ASD and typically developing children. 1,2 Furthermore, specific gut microbes may modulate ASD-related behaviour through their metabolites. 1 However, another study proposed that the GM is not the central driver of ASD symptoms; rather, the presence of restricted interests associated with ASD and a more limited dietary variety have been linked to reduced diversity in the GM. 3 The relationship between the GM and ASD remains enigmatic and complex as the age-old philosophical conundrum that has long been debated: which came first, the chicken or the egg? Some open-label studies 4-6 have demonstrated that FMT improved the core symptoms of patients with ASD, though these studies lacked comparable control groups, which may lead to disregard of potential placebo effects on efficacy evaluation. Therefore, we conducted this study.A total of 103 eligible participants (Figure 1) were enrolled and randomised to receive either FMT or a placebo. These agents were administered during two 6day periods in the hospital, the first occurring in the initial week and the second in the fifth week of the study. Patients were not hospitalised during the interval between treatments. FMT capsules from five healthy donors were